AnaptysBio Inc., a clinical-stage biotechnology company, announced positive results from its Phase 2b trial of rosnilimab, an investigational drug targeting PD-1+ T cells, in patients with moderate-to-severe rheumatoid arthritis $(RA)$. The trial demonstrated that rosnilimab achieved efficacy comparable to JAK inhibitors, with improvements in clinically meaningful measures such as low disease activity and remission over a six-month period. The drug also showed favorable safety and tolerability profiles compared to standard biologics or JAKs, with durable responses lasting at least two months after discontinuation. AnaptysBio will host an investor call and webcast to discuss the findings on June 3, 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。